Clinical Trial Update: A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas [Phase 1]

View source ↗

Summary

DR-0202 is being studied in a Phase 1 trial across multiple locally advanced or metastatic carcinomas; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castrate-resistant Prostate Cancer
• Cervical Cancer
• Endometrial Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Ductal Adenocarcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• DR-0202

Snippet

Sponsor: Dren Bio | Conditions: Triple Negative Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Status: RECRUITING